Comments
Loading...

Jazz Pharmaceuticals Analyst Ratings

JAZZNASDAQ
Logo brought to you by Benzinga Data
$107.01
-2.45-2.24%
At close: -
$107.01
0.000.00%
After Hours: 4:36 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$230.00
Lowest Price Target1
$147.00
Consensus Price Target1
$189.20

Jazz Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:JAZZ | Benzinga

Jazz Pharmaceuticals PLC has a consensus price target of $189.2 based on the ratings of 21 analysts. The high is $230 issued by Truist Securities on March 6, 2025. The low is $147 issued by Piper Sandler on May 7, 2025. The 3 most-recent analyst ratings were released by Baird, RBC Capital, and Piper Sandler on May 7, 2025, respectively. With an average price target of $158 between Baird, RBC Capital, and Piper Sandler, there's an implied 47.65% upside for Jazz Pharmaceuticals PLC from these most-recent analyst ratings.

Analyst Trends and Forecast
4
Dec 24
6
1
Feb
5
Mar
1
Apr
5
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Baird
RBC Capital
Piper Sandler
Morgan Stanley
Needham

1calculated from analyst ratings

Analyst Ratings for Jazz Pharmaceuticals

Buy NowGet Alert
05/07/2025Buy Now44.85%Baird
Joel Beatty67%
$167 → $155MaintainsOutperformGet Alert
05/07/2025Buy Now60.73%RBC Capital
Gregory Renza49%
$182 → $172MaintainsOutperformGet Alert
05/07/2025Buy Now37.37%Piper Sandler
David Amsellem77%
$176 → $147ReiteratesOverweight → OverweightGet Alert
05/07/2025Buy Now55.13%Morgan Stanley
Jeffrey Hung51%
$183 → $166MaintainsOverweightGet Alert
05/07/2025Buy Now86.9%Needham
Ami Fadia57%
$200 → $200ReiteratesBuy → BuyGet Alert
04/10/2025Buy Now96.24%Needham
Ami Fadia57%
$210 → $210ReiteratesBuy → BuyGet Alert
03/10/2025Buy Now102.78%HC Wainwright & Co.
Oren Livnat60%
$200 → $217MaintainsBuyGet Alert
03/07/2025Buy Now71.01%Morgan Stanley
Jeffrey Hung51%
$175 → $183Assumes → OverweightGet Alert
03/07/2025Buy Now67.27%UBS
Ashwani Verma47%
$145 → $179UpgradeNeutral → BuyGet Alert
03/06/2025Buy Now114.93%Truist Securities
Gregory Fraser63%
$220 → $230MaintainsBuyGet Alert
03/05/2025Buy Now96.24%Needham
Ami Fadia57%
$210 → $210ReiteratesBuy → BuyGet Alert
02/27/2025Buy Now86.9%Barclays
Balaji Prasad55%
$190 → $200MaintainsOverweightGet Alert
02/26/2025Buy Now40.17%Cantor Fitzgerald
Charles Duncan69%
$140 → $150DowngradeOverweight → NeutralGet Alert
02/26/2025Buy Now64.47%Piper Sandler
David Amsellem77%
$163 → $176ReiteratesOverweight → OverweightGet Alert
02/26/2025Buy Now66.34%RBC Capital
Gregory Renza49%
$179 → $178MaintainsOutperformGet Alert
02/26/2025Buy Now95.31%JP Morgan
Jessica Fye67%
$200 → $209MaintainsOverweightGet Alert
02/26/2025Buy Now96.24%Needham
Ami Fadia57%
$205 → $210MaintainsBuyGet Alert
02/13/2025Buy Now58.86%Wells Fargo
Mohit Bansal67%
$130 → $170UpgradeEqual-Weight → OverweightGet Alert
12/12/2024Buy Now52.32%Piper Sandler
David Amsellem77%
$163 → $163ReiteratesOverweight → OverweightGet Alert
12/12/2024Buy Now67.27%RBC Capital
Gregory Renza49%
$179 → $179ReiteratesOutperform → OutperformGet Alert
12/12/2024Buy Now93.44%Needham
Ami Fadia57%
$207 → $207ReiteratesBuy → BuyGet Alert
12/10/2024Buy Now67.27%RBC Capital
Gregory Renza49%
$179 → $179ReiteratesOutperform → OutperformGet Alert
11/22/2024Buy Now86.9%HC Wainwright & Co.
Oren Livnat60%
$200 → $200ReiteratesBuy → BuyGet Alert
11/21/2024Buy Now93.44%Needham
Ami Fadia57%
$207 → $207ReiteratesBuy → BuyGet Alert
11/21/2024Buy Now52.32%Piper Sandler
David Amsellem77%
$166 → $163ReiteratesOverweight → OverweightGet Alert
11/18/2024Buy Now51.39%Baird
Joel Beatty67%
$154 → $162MaintainsOutperformGet Alert
11/07/2024Buy Now82.23%TD Cowen—$200 → $195MaintainsBuyGet Alert
11/07/2024Buy Now93.44%Needham
Ami Fadia57%
$207 → $207ReiteratesBuy → BuyGet Alert
10/23/2024Buy Now67.27%RBC Capital
Gregory Renza49%
$175 → $179MaintainsOutperformGet Alert
10/04/2024Buy Now63.54%RBC Capital
Gregory Renza49%
$174 → $175MaintainsOutperformGet Alert
09/10/2024Buy Now91.57%Needham
Ami Fadia57%
$205 → $205ReiteratesBuy → BuyGet Alert
09/09/2024Buy Now30.83%Cantor Fitzgerald
Charles Duncan69%
$140 → $140ReiteratesOverweight → OverweightGet Alert
08/19/2024Buy Now88.77%JP Morgan
Jessica Fye67%
$190 → $202MaintainsOverweightGet Alert
08/01/2024Buy Now30.83%Cantor Fitzgerald
Charles Duncan69%
$140 → $140ReiteratesOverweight → OverweightGet Alert
08/01/2024Buy Now55.13%Piper Sandler
David Amsellem77%
$188 → $166MaintainsOverweightGet Alert
08/01/2024Buy Now62.6%RBC Capital
Gregory Renza49%
$175 → $174MaintainsOutperformGet Alert
08/01/2024Buy Now12.14%Wells Fargo
Mohit Bansal67%
$140 → $120MaintainsEqual-WeightGet Alert
08/01/2024Buy Now91.57%Needham
Ami Fadia57%
$208 → $205MaintainsBuyGet Alert
08/01/2024Buy Now86.9%HC Wainwright & Co.
Oren Livnat60%
$200 → $200ReiteratesBuy → BuyGet Alert
08/01/2024Buy Now43.91%Baird
Joel Beatty67%
$160 → $154MaintainsOutperformGet Alert
07/12/2024Buy Now40.17%Morgan Stanley
Jeffrey Hung51%
$160 → $150MaintainsEqual-WeightGet Alert
07/02/2024Buy Now5.6%UBS
Ashwani Verma47%
$117 → $113MaintainsNeutralGet Alert
06/20/2024Buy Now96.24%Needham
Ami Fadia57%
$222 → $210MaintainsBuyGet Alert
06/05/2024Buy Now57.93%Goldman Sachs
Madhu Kumar72%
→ $169Initiates → BuyGet Alert
05/03/2024Buy Now86.9%HC Wainwright & Co.
Oren Livnat60%
$200 → $200ReiteratesBuy → BuyGet Alert
05/03/2024Buy Now86.9%Barclays
Balaji Prasad55%
$230 → $200MaintainsOverweightGet Alert
05/02/2024Buy Now107.46%Needham
Ami Fadia57%
$222 → $222ReiteratesBuy → BuyGet Alert
04/10/2024Buy Now68.21%Cantor Fitzgerald
Charles Duncan69%
$180 → $180ReiteratesOverweight → OverweightGet Alert
03/22/2024Buy Now68.21%Cantor Fitzgerald
Charles Duncan69%
$180 → $180ReiteratesOverweight → OverweightGet Alert
03/22/2024Buy Now77.55%JP Morgan
Jessica Fye67%
$170 → $190MaintainsOverweightGet Alert
03/20/2024Buy Now105.59%Needham
Ami Fadia57%
$220 → $220ReiteratesBuy → BuyGet Alert
03/20/2024Buy Now86.9%Truist Securities
Joon Lee77%
→ $200ReiteratesBuy → BuyGet Alert
03/20/2024Buy Now75.68%Piper Sandler
David Amsellem77%
$171 → $188ReiteratesOverweight → OverweightGet Alert
03/15/2024Buy Now114.93%Stifel
Annabel Samimy66%
$225 → $230MaintainsBuyGet Alert
03/14/2024Buy Now86.9%HC Wainwright & Co.
Oren Livnat60%
$204 → $200MaintainsBuyGet Alert
03/01/2024Buy Now114.93%Barclays
Balaji Prasad55%
$235 → $230MaintainsOverweightGet Alert
03/01/2024Buy Now22.42%UBS
Ashwani Verma47%
$135 → $131MaintainsNeutralGet Alert
02/29/2024Buy Now82.23%RBC Capital
Gregory Renza49%
$195 → $195ReiteratesOutperform → OutperformGet Alert
02/29/2024Buy Now68.21%Cantor Fitzgerald
Charles Duncan69%
$180 → $180ReiteratesOverweight → OverweightGet Alert
02/29/2024Buy Now58.86%JP Morgan
Jessica Fye67%
$180 → $170MaintainsOverweightGet Alert
02/29/2024Buy Now105.59%Needham
Ami Fadia57%
$225 → $220MaintainsBuyGet Alert
01/29/2024Buy Now119.61%Barclays
Balaji Prasad55%
$240 → $235MaintainsOverweightGet Alert
01/03/2024Buy Now49.52%Baird
Joel Beatty67%
→ $160Initiates → OutperformGet Alert
12/04/2023Buy Now86.9%Truist Securities
Joon Lee77%
→ $200ReiteratesBuy → BuyGet Alert
11/29/2023Buy Now110.26%Needham
Ami Fadia57%
→ $225ReiteratesBuy → BuyGet Alert
11/27/2023Buy Now26.16%UBS
Ashwani Verma47%
$170 → $135DowngradeBuy → NeutralGet Alert
11/09/2023Buy Now78.49%RBC Capital
Gregory Renza49%
$200 → $191MaintainsOutperformGet Alert
11/09/2023Buy Now110.26%Needham
Ami Fadia57%
$226 → $225MaintainsBuyGet Alert
09/29/2023Buy Now—Raymond James
Gary Nachman58%
—Initiates → Market PerformGet Alert
08/22/2023Buy Now68.21%Cantor Fitzgerald
Brandon Folkes40%
→ $180ReiteratesOverweight → OverweightGet Alert
08/14/2023Buy Now68.21%Cantor Fitzgerald
Brandon Folkes40%
$210 → $180MaintainsOverweightGet Alert
08/11/2023Buy Now90.64%HC Wainwright & Co.
Oren Livnat60%
→ $204ReiteratesBuy → BuyGet Alert
08/10/2023Buy Now102.78%B of A Securities
Jason Gerberry59%
$204 → $217MaintainsBuyGet Alert
08/10/2023Buy Now87.83%RBC Capital
Gregory Renza49%
$203 → $201MaintainsOutperformGet Alert
08/10/2023Buy Now111.2%Needham
Ami Fadia57%
→ $226ReiteratesBuy → BuyGet Alert
08/07/2023Buy Now111.2%Needham
Ami Fadia57%
→ $226ReiteratesBuy → BuyGet Alert
07/11/2023Buy Now74.75%Morgan Stanley
Jeffrey Hung51%
$187 → $187ReiteratesEqual-Weight → Equal-WeightGet Alert
06/05/2023Buy Now111.2%Needham
Ami Fadia57%
→ $226ReiteratesBuy → BuyGet Alert
05/30/2023Buy Now111.2%Needham
Ami Fadia57%
$212 → $226ReiteratesBuy → BuyGet Alert
05/15/2023Buy Now90.64%HC Wainwright & Co.
Oren Livnat60%
→ $204ReiteratesBuy → BuyGet Alert
05/15/2023Buy Now98.11%Needham
Ami Fadia57%
→ $212ReiteratesBuy → BuyGet Alert
05/11/2023Buy Now88.77%RBC Capital
Gregory Renza49%
$207 → $202MaintainsOutperformGet Alert
05/11/2023Buy Now98.11%Needham
Ami Fadia57%
$205 → $212MaintainsBuyGet Alert
03/06/2023Buy Now90.64%HC Wainwright & Co.
Oren Livnat60%
→ $204Reiterates → BuyGet Alert
03/03/2023Buy Now98.11%Goldman Sachs
Madhu Kumar72%
$190 → $212MaintainsBuyGet Alert
03/02/2023Buy Now91.57%Needham
Ami Fadia57%
$210 → $205MaintainsBuyGet Alert
12/09/2022Buy Now77.55%Goldman Sachs
Madhu Kumar72%
$192 → $190UpgradeNeutral → BuyGet Alert
11/10/2022Buy Now79.42%Goldman Sachs
Madhu Kumar72%
$170 → $192MaintainsNeutralGet Alert
11/10/2022Buy Now93.44%RBC Capital
Gregory Renza49%
$206 → $207MaintainsOutperformGet Alert
11/10/2022Buy Now94.37%Needham
Ami Fadia57%
$210 → $208MaintainsBuyGet Alert
09/29/2022Buy Now58.86%Goldman Sachs
Madhu Kumar72%
$148 → $170MaintainsNeutralGet Alert
09/21/2022Buy Now38.3%Goldman Sachs
Madhu Kumar72%
$192 → $148MaintainsNeutralGet Alert
08/04/2022Buy Now75.68%BMO Capital
Gary Nachman58%
$185 → $188MaintainsOutperformGet Alert
08/04/2022Buy Now74.75%Morgan Stanley
Jeffrey Hung51%
$174 → $187MaintainsEqual-WeightGet Alert
08/04/2022Buy Now78.49%UBS
Ashwani Verma47%
$194 → $191MaintainsBuyGet Alert
08/04/2022Buy Now96.24%SVB Leerink
Marc Goodman73%
$200 → $210MaintainsOutperformGet Alert
06/14/2022Buy Now81.29%UBS
Ashwani Verma47%
→ $194Initiates → BuyGet Alert

FAQ

Q

What is the target price for Jazz Pharmaceuticals (JAZZ) stock?

A

The latest price target for Jazz Pharmaceuticals (NASDAQ:JAZZ) was reported by Baird on May 7, 2025. The analyst firm set a price target for $155.00 expecting JAZZ to rise to within 12 months (a possible 44.85% upside). 44 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Jazz Pharmaceuticals (JAZZ)?

A

The latest analyst rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) was provided by Baird, and Jazz Pharmaceuticals maintained their outperform rating.

Q

When was the last upgrade for Jazz Pharmaceuticals (JAZZ)?

A

The last upgrade for Jazz Pharmaceuticals PLC happened on March 7, 2025 when UBS raised their price target to $179. UBS previously had a neutral for Jazz Pharmaceuticals PLC.

Q

When was the last downgrade for Jazz Pharmaceuticals (JAZZ)?

A

The last downgrade for Jazz Pharmaceuticals PLC happened on February 26, 2025 when Cantor Fitzgerald changed their price target from $140 to $150 for Jazz Pharmaceuticals PLC.

Q

When is the next analyst rating going to be posted or updated for Jazz Pharmaceuticals (JAZZ)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jazz Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jazz Pharmaceuticals was filed on May 7, 2025 so you should expect the next rating to be made available sometime around May 7, 2026.

Q

Is the Analyst Rating Jazz Pharmaceuticals (JAZZ) correct?

A

While ratings are subjective and will change, the latest Jazz Pharmaceuticals (JAZZ) rating was a maintained with a price target of $167.00 to $155.00. The current price Jazz Pharmaceuticals (JAZZ) is trading at is $107.01, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch